Sign in Subscribe
Cancer research

Doxorubicin-Loaded Nanoparticles Show Promise for Breast Cancer Treatment

Strategic Insights

— 1 min read

Researchers at the School of Pharmaceutical Sciences have developed a new approach to breast cancer treatment using doxorubicin-loaded salicylic acid cross-linked chitosan nanoparticles. These nanoparticles, known as Dox-SA-CH-NPs, were designed to minimize systemic toxicity and improve therapeutic efficacy. The study found that Dox-SA-CH-NPs exhibited a mean particle size of 110.9 ± 0.2 nm, a zeta potential of 33.25 ± 0.2 mV, and an encapsulation efficiency of 93.4 ± 0.01 %. The drug release from Dox-SA-CH-NPs was sustained over 72 hours, with 48.05 ± 2.3 % of the drug released.

Key Takeaways:

  • The researchers developed a novel approach to breast cancer treatment using doxorubicin-loaded salicylic acid cross-linked chitosan nanoparticles (Dox-SA-CH-NPs).
  • Dox-SA-CH-NPs had a mean particle size of 110.9 ± 0.2 nm, a zeta potential of 33.25 ± 0.2 mV, and an encapsulation efficiency of 93.4 ± 0.01 %.
  • The drug release from Dox-SA-CH-NPs was sustained over 72 hours, with 48.05 ± 2.3 % of the drug released.
  • In vitro and in vivo studies confirmed the accelerated tissue regeneration ability of SA-CH-NPs and the effective tumor inhibition by Dox-SA-CH-NPs.
  • Higher collagen deposition was observed on days 4 and 9 in the SA-CH-NP-treated group.
  • The study concluded that Dox-SA-CH-NPs are a promising localized chemotherapy strategy to improve post-surgical outcomes in breast cancer treatment.

Statistics:

  • 93.4 ± 0.01 % of doxorubicin was encapsulated in Dox-SA-CH-NPs.
  • 110.9 ± 0.2 nm is the mean particle size of Dox-SA-CH-NPs.
  • 33.25 ± 0.2 mV is the zeta potential of Dox-SA-CH-NPs.
  • 48.05 ± 2.3 % of doxorubicin was released from Dox-SA-CH-NPs over 72 hours.

Sources:

  • Doxorubicin loaded salicylic acid crosslinked chitosan nanoparticles as postsurgical implants for breast cancer. International Journal of Biological Macromolecules, 2025:145874.
  • School of Pharmaceutical Sciences Reports Findings in Breast Cancer (Doxorubicin loaded salicylic acid crosslinked chitosan nanoparticles as postsurgical implants for breast cancer). Nanotechnology Weekly. July 21, 2025; p 3488.
  • International Journal of Biological Macromolecules can be contacted at: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.
  • Additional information may be obtained by contacting Rakesh Kumar Sahoo, School of Pharmaceutical Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India.

Read more